Showing results (301-310 of 482) with videos related to

Sort By:
Pageof 49
Cancer Discovery|December 18, 2012
The mTORC1 inhibitor everolimus prevents and treats Eμ-Myc lymphoma by restoring oncogene-induced senescenceMeaghan Wall, Gretchen Poortinga, Kym L Stanley, et al.
Pigment Cell & Melanoma Research|February 6, 2014
Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell linesRichard J Young, Kelly Waldeck, Claire Martin, et al.
Science Signaling|September 1, 2011
AKT promotes rRNA synthesis and cooperates with c-MYC to stimulate ribosome biogenesis in cancerJoanna C Chan, Katherine M Hannan, Kim Riddell, et al.
Arthritis and Rheumatism|November 30, 2006
A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in sclerodermaRachel K Hoyles, Ross W Ellis, Jessica Wellsbury, et al.
Oncotarget|July 9, 2016
Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signalingJaclyn Quin, Keefe T Chan, Jennifer R Devlin, et al.
Cancer Discovery|March 28, 2018
Identification of Pik3ca Mutation as a Genetic Driver of Prostate Cancer That Cooperates with Pten Loss to Accelerate Progression and Castration-Resistant GrowthHelen B Pearson, Jason Li, Valerie S Meniel, et al.
European Journal of Cancer (Oxford, England : 1990)|September 10, 2013
Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitorsKaren E Sheppard, Carleen Cullinane, Katherine M Hannan, et al.
The Journal of Clinical Investigation|January 5, 2012
An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in miceKathryn M Kinross, Karen G Montgomery, Margarete Kleinschmidt, et al.
Plos Medicine|November 30, 2016
The Long-Term Safety, Public Health Impact, and Cost-Effectiveness of Routine Vaccination with a Recombinant, Live-Attenuated Dengue Vaccine (Dengvaxia): A Model Comparison StudyStefan Flasche, Mark Jit, Isabel Rodríguez-Barraquer, et al.
Cancer Cell|July 14, 2012
Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53Megan J Bywater, Gretchen Poortinga, Elaine Sanij, et al.
Pageof 49